Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical sinecatechins as adjuvant to trichloroacetic acid for anal HSIL in HIV-1 infected adults
2024-519782-21-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Mar 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Theaphenon E in anal intraepithelial neoplasia (AIN) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Cumulative proportion of patients free of HSIL at 48 weeks post-treatment. Planned start Mar 2025; status: authorised.
02
Drugs
Theaphenon E
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on 2024-519782-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519782-21-00.